Literature DB >> 18609741

Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review.

Laura C Coates1, R Rox Anderson, Oliver Fitzgerald, Alice B Gottlieb, Stephen G Kelly, Ennio Lubrano, Dennis G McGonagle, Ignazio Olivieri, Christopher T Ritchlin, Ai Lyn Tan, Kurt De Vlam, Philip S Helliwell.   

Abstract

This article summarizes a presentation on imaging of skin and joints in patients with psoriasis and psoriatic arthritis (PsA) from the 2007 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Plain radiography provides valuable insights into the pathogenesis of PsA but is limited because only calcified tissue can be imaged. Newer techniques such as magnetic resonance imaging (MRI) and ultrasound (US) provide additional clues to the pathogenesis of this peripheral, axial, and dermatologic disease. MRI and to a lesser extent US allow visualization of articular and periarticular structures, showing widespread juxtaarticular inflammation in PsA. Bone edema, a surrogate marker of inflammation, can occur throughout the digit in psoriatic dactylitis. Localization of inflammatory change at the juxtaarticular entheses suggests this as the primary site of inflammation. Recent imaging studies provide insights into the relationship between nail and articular disease, demonstrating extension of inflammation from entheseal structures at the distal interphalangeal joint to the nail bed, but the temporal or anatomical progression of these changes remains elusive. Imaging of the skin lags behind that of the articular structures, partly because the skin is readily available for biopsy; however, newer techniques such as laser Doppler imaging provide insights into angiogenesis at the advancing edge of psoriatic plaques. Future work will explore the relationship between immunohistology and imaging of skin and joints. Improvements in imaging articular soft tissues with ultra-short echo time MRI and skin with multiphoton fluorescence microscopy promise insights into anatomical and functional changes.

Entities:  

Mesh:

Year:  2008        PMID: 18609741

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Clinical utility of ultrasonography in spondyloarthropathies.

Authors:  Roger D Sturrock
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

2.  [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch].

Authors:  J Wohlrab; F Gilbrich; L Wolff; M Fischer; S Philipp
Journal:  Hautarzt       Date:  2017-03       Impact factor: 0.751

Review 3.  Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.

Authors:  Philip J Mease; April W Armstrong
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 4.  Secukinumab for ankylosing spondylitis and psoriatic arthritis.

Authors:  Ennio Lubrano; Fabio Massimo Perrotta
Journal:  Ther Clin Risk Manag       Date:  2016-10-21       Impact factor: 2.423

5.  Ultrasonographic Enthesopathy and Disease Activity in Psoriatic Arthritis.

Authors:  Mohieldin M Ahmed; Gehan Gamal Elolemy; Aziz K Alfeeli; Ayyoub B Baqer; Adela M Gad
Journal:  Open Access Maced J Med Sci       Date:  2017-08-11

6.  A sonographic spectrum of psoriatic arthritis: "the five targets".

Authors:  Marwin Gutierrez; Emilio Filippucci; Rossella De Angelis; Giorgio Filosa; David Kane; Walter Grassi
Journal:  Clin Rheumatol       Date:  2009-10-24       Impact factor: 2.980

7.  The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis.

Authors:  Laura C Coates; Nuria Navarro-Coy; Sarah R Brown; Sarah Brown; Lucy McParland; Howard Collier; Emma Skinner; Jennifer Law; Anna Moverley; Sue Pavitt; Claire Hulme; Paul Emery; Philip G Conaghan; Philip S Helliwell
Journal:  BMC Musculoskelet Disord       Date:  2013-03-21       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.